1. Home
  2. INSM vs WDS Comparison

INSM vs WDS Comparison

Compare INSM & WDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • WDS
  • Stock Information
  • Founded
  • INSM 1988
  • WDS 1954
  • Country
  • INSM United States
  • WDS Australia
  • Employees
  • INSM N/A
  • WDS N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • WDS Oil & Gas Production
  • Sector
  • INSM Health Care
  • WDS Energy
  • Exchange
  • INSM Nasdaq
  • WDS Nasdaq
  • Market Cap
  • INSM 26.0B
  • WDS 23.9B
  • IPO Year
  • INSM 2000
  • WDS N/A
  • Fundamental
  • Price
  • INSM $145.86
  • WDS $15.29
  • Analyst Decision
  • INSM Strong Buy
  • WDS Hold
  • Analyst Count
  • INSM 18
  • WDS 1
  • Target Price
  • INSM $146.81
  • WDS N/A
  • AVG Volume (30 Days)
  • INSM 2.0M
  • WDS 701.9K
  • Earning Date
  • INSM 10-30-2025
  • WDS 08-18-2025
  • Dividend Yield
  • INSM N/A
  • WDS 6.67%
  • EPS Growth
  • INSM N/A
  • WDS 58.72
  • EPS
  • INSM N/A
  • WDS 1.54
  • Revenue
  • INSM $398,105,000.00
  • WDS $13,781,000,000.00
  • Revenue This Year
  • INSM $31.95
  • WDS N/A
  • Revenue Next Year
  • INSM $125.46
  • WDS N/A
  • P/E Ratio
  • INSM N/A
  • WDS $9.81
  • Revenue Growth
  • INSM 21.15
  • WDS 9.53
  • 52 Week Low
  • INSM $60.40
  • WDS $11.26
  • 52 Week High
  • INSM $149.08
  • WDS $18.43
  • Technical
  • Relative Strength Index (RSI)
  • INSM 72.40
  • WDS 30.46
  • Support Level
  • INSM $138.73
  • WDS $16.04
  • Resistance Level
  • INSM $148.22
  • WDS $16.37
  • Average True Range (ATR)
  • INSM 3.85
  • WDS 0.21
  • MACD
  • INSM -0.97
  • WDS -0.15
  • Stochastic Oscillator
  • INSM 78.08
  • WDS 0.26

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About WDS Woodside Energy Group Limited

Incorporated in 1954 and named after the small Victorian town of Woodside, Woodside's early exploration focus moved from Victoria's Gippsland Basin to Western Australia's Carnarvon Basin. First LNG production from the North West Shelf came in 1984. BHP Billiton and Shell each had 40% shareholdings before BHP sold out in 1994 and Shell sold down to 34%. In 2010, Shell further decreased its shareholding to 24%. Woodside has the potential to become the most LNG-leveraged company globally.

Share on Social Networks: